Immunogenicity of branched polyethylene glycol modified interferon alpha.
CONCLUSION: The incidence of treatment-induced Nab in Pegasys group was significantly higher than the Pegberon group. Baseline ATA, induced ATA and baseline NAb all affected the efficacy. The profiles of potential immunogenicity-related AR were similar between two drug groups, indicating the immunogenicity had no significant adverse effect on safety.
PMID: 29103340 [PubMed - as supplied by publisher] (Source: Immunopharmacology and Immunotoxicology)
Source: Immunopharmacology and Immunotoxicology - November 7, 2017 Category: Allergy & Immunology Tags: Immunopharmacol Immunotoxicol Source Type: research
Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection
In this study, we aim to identify patient characteristics that predict severe thrombocytopenia induced by peginterferon alfa-2a in hepatitis C virus–infected patients. Demographic, clinical, and genetic data collected from patients with chronic hepatitis C virus infection (n = 232; age ≥18 years) who received peginterferon alfa-2a following eltrombopag treatment. Predictors of severe thrombocytopenia (platelet count below 50 GI/L) were identified using a 2-step approach: First, univariate analysis, using χ2 test for categorical variables and t test for continuous variables, was performed to identify possible predictor...
Source: American Journal of Therapeutics - November 1, 2017 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research
Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals
Conclusion In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HCV patients. (Source: Hepatobiliary and Pancreatic Diseases International)
Source: Hepatobiliary and Pancreatic Diseases International - October 7, 2017 Category: Gastroenterology Source Type: research
Directly observed therapy of sofosbuvir/ribavirin +/ − peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C‐DOT)
Summary
We assessed the feasibility of field‐based directly observed therapy (DOT) with minimal monitoring to deliver HCV treatment to people with a history of drug use in Chennai, India. Fifty participants were randomized 1:1 to sofosbuvir+peginterferon alfa 2a+ribavirin (SOF+PR) for 12 weeks (Arm 1) vs sofosbuvir+ribavirin (SOF+R) for 24 weeks (Arm 2). SOF+R was delivered daily at participant chosen venues and weekly peginterferon injections at the study clinic. HCV RNA testing was performed to confirm active HCV infection and sustained virologic response 12 weeks after treatment completion (SVR12). No baseline geno...
Source: Journal of Viral Hepatitis - August 14, 2017 Category: Infectious Diseases Authors: S. S. Solomon, M. S. Sulkowski, P. Amrose, A. K. Srikrishnan, A. M. McFall, B. Ramasamy, M. S. Kumar, S. Anand, D. L. Thomas, S. H. Mehta Tags: ORIGINAL ARTICLE Source Type: research
Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients
This study suggests symptomatic response and tumor control effect with interferon-alpha in progressive MPPGLs. (Source: Hormones and Cancer)
Source: Hormones and Cancer - July 26, 2017 Category: Cancer & Oncology Source Type: research
Directly Observed Therapy of Sofosbuvir/Ribavirin +/ ‐ Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C‐DOT)
ConclusionsField‐based DOT of HCV therapy without real‐time HCV RNA monitoring was feasible; however achieving 100% adherence was challenging. SOF+PR appeared superior to SOF+R in achieving SVR12, even when doses were missed with no discontinuations due to side effects. Further exploration of short duration treatment with peginterferon plus direct acting antivirals is warranted.This article is protected by copyright. All rights reserved. (Source: Journal of Viral Hepatitis)
Source: Journal of Viral Hepatitis - July 1, 2017 Category: Infectious Diseases Authors: Sunil S Solomon, Mark S Sulkowski, Pradeep Amrose, Aylur K Srikrishnan, Allison M McFall, Balakrishnan Ramasamy, Muniratnam S Kumar, Santhanam Anand, David L Thomas, Shruti H Mehta Tags: Original Paper Source Type: research
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study
ConclusionBoth dual and triple therapy regimes resulted in SVR rates of >95% in CHC genotype 3 who were naive non-cirrhotics. However, the SVR rates were low in treatment-experienced cirrhotics. (Source: Hepatology International)
Source: Hepatology International - March 31, 2017 Category: Infectious Diseases Source Type: research
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study
ConclusionsDCV + PegIFN/RBV led to sustained HCV virologic response in the majority of HIV-1-HCV-coinfected patients, regardless of concomitant ART. HIV control was not compromised and no new safety signals were identified. This study supports DCV use in HIV-1-HCV-coinfected patients, while allowing the vast ma jority of patients to remain on their existing ART regimen. (Source: Hepatology International)
Source: Hepatology International - February 15, 2017 Category: Infectious Diseases Source Type: research
Tolerability and efficacy of pegylated consensus interferon- α in the treatment of chronic hepatitis C.
This study aimed to explore and evaluate the tolerability and antiviral activity of pegylated recombinant human consensus interferon-α (PEG-CIFN) in adults with hepatitis C virus (HCV) infection. A total of 48 adult subjects chronically infected with HCV were divided into five groups, which were treated separately with PEG-CIFN 1.0 µg/kg (n=10), 1.5 µg/kg (n=10), 2.0 µg/kg (n=9) or 3.0 µg/kg (n=10), or pegylated IFN α-2a (Pegasys) 180 µg (n=9) as controls. Symptoms were observed and laboratory results collected to monitor adverse reactions, adjust drug dosage and evaluate tolerability. The thrombocytopenic effects i...
Source: Experimental and Therapeutic Medicine - January 27, 2017 Category: Journals (General) Tags: Exp Ther Med Source Type: research
Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review.
Conclusion A range of agents (small-molecules, natural products, macrocycles, and non-small molecules) have been described as having the ability to suppress the secretion of HBsAg (in vitro, as well as in vivo in animal models, pre-clinical models, and clinical trials), and this review will focus on an overview of the different agents, and different strategies being pursued to develop methods of inhibiting the secretion of HBsAg, with a view to the cure of HBV.
PMID: 28056752 [PubMed - as supplied by publisher] (Source: Infectious Disorders Drug Targets)
Source: Infectious Disorders Drug Targets - January 3, 2017 Category: Infectious Diseases Authors: Baugh SD Tags: Infect Disord Drug Targets Source Type: research
Tenofovir Alafenamide (Vemlidy) for Hepatitis B
Date: January 2, 2017
Issue #:
1511Summary:
The FDA has approved tenofovir alafenamide
(Vemlidy– Gilead) for treatment of chronic hepatitis
B virus (HBV) infection in adults with compensated
liver disease. It is the first single-drug product
containing tenofovir alafenamide (TAF), a prodrug of
the nucleotide reverse transcriptase inhibitor tenofovir,
to become available; several combination products
containing TAF are approved for treatment of HIV-1
infection. Tenofovir disoproxil fumarate (TDF;Viread–
Gilead), another tenofovir prodrug, has been used for
many years for treat...
Source: The Medical Letter - December 14, 2016 Category: Drugs & Pharmacology Authors: admin Tags: Adefovir Baraclude Entecavir Epivir-HBV hepatitis b Hepsera Heptovir lamivudine HBV Pegasys Peginterferon alfa-2a Sebivo telbivudine Tenofovir tenofovir alafenamide tyzeka Vemlidy Viread Source Type: research
Rabbit Syndrome developing during peginterferon alfa-2a use in Chronic Hepatitis C.
Authors: Soyer OM, Pehlivan A, Ormeci CA, Baran B, Sahin T
PMID: 27595306 [PubMed - as supplied by publisher] (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 8, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Bevacizumab and interferon reduce venous recanalization following sclerotherapy
The treatment of venous malformations is difficult because these lesions frequently recur after resection or sclerotherapy. The purpose of this study was to determine whether recanalization of sclerosed venous lumens could be prevented with systemic angiogenic inhibition using bevacizumab or peginterferon alfa-2a. (Source: Journal of Pediatric Surgery)
Source: Journal of Pediatric Surgery - August 25, 2016 Category: Surgery Authors: Ann M. Kulungowski, Aladdin H. Hassanein, Carolyn C. Foster, Arin K. Greene, Steven J. Fishman Source Type: research
Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies
ConclusionIn conclusion, a simple scoring system can be used to identify GT4-infected patients with a high probability of achieving an SVR with PegIFN alfa-2a/RBV.FundingF. Hoffmann-La Roche Ltd. (Source: Advances in Therapy)
Source: Advances in Therapy - August 11, 2016 Category: Drugs & Pharmacology Source Type: research
CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study
Conclusions: PEG-INF-α2a plus ADV combination therapy is safe and superior to PEG-INF-α2amonotherapyfor decreasing serum HBV DNA and normalizing the ALT level but has no significant impact on the rate of HBeAg seroconversion and HBsAg loss. Adding ADV at week 12 may be an optimal combination strategy. (Source: Medicine)
Source: Medicine - August 1, 2016 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research
